Mucommune
Thomas Moench is the VP, Clinical Development at Mucommune.
This person is not in any offices
Mucommune
Mucommune is a privately-held preclinical stage company launched based on the “muco-trapping” monoclonal antibodies (mAb) platform developed at Johns Hopkins University and University of North Carolina at Chapel Hill.